$ChemoCentryx(CCXI.US$
ChemoCentryx, Inc.'s (NASDAQ:CCXI) avacopan was the only new molecular entity approved during the month. NMEs are new drug products containing an active ingredient that is marketed for the first time in the U.S. Avacopan, which is to go by the brand name Tavneos, has been approved for treating small blood vessel damage.
It’s all good. let’s go!
ChemoCentryx, Inc.'s (NASDAQ:CCXI) avacopan was the only new molecular entity approved during the month. NMEs are new drug products containing an active ingredient that is marketed for the first time in the U.S. Avacopan, which is to go by the brand name Tavneos, has been approved for treating small blood vessel damage.
It’s all good. let’s go!
8
$Arcturus Therapeutics(ARCT.US$- do your DD- on all positive news from here!
“The most important thing here is that WHO chose ARCT for one of the 4 vaccine candidates and sponsor and fund phase 3 for arct021.
ARCT has very good mRNA platforms, and hence very valuable IPs. Arct021 was the original vaccine candidate to tackle covid19. With the emergence of variants, ARCT has quickly updated and came up with arct154 and arct165. If ARCT can get EUA in Vietnam for arct154, the potential would be immense. Arct021 is a one dose vaccine and that has a lot of advantages. Despite the fact that many may already have been vaccinated, but arct021 can still be effective as a one dose vaccine since from research reports, neutralising antibodies dropped to very low levels after 6 months with the other vaccines. So, arct021, arct154 and arct165 still have very good potentials in the vaccine market and can also be as booster shots.
In the future, if we have another outbreak of diseases, ARCT can be the go-to company to quickly develop a vaccine besides BionTech and Moderna. The mRNA platforms of ARCT, in my opinion, is better than its competitors. Some big pharmas are behind the curve in mRNA technology and they may look to acquire ARCT. The only weakness for ARCT was that it was a standalone biotech and there was no support or tie-up with another big pharma during the covid crisis as compared to BionTech with Pfizer, and Moderna getting lots of funding etc....” qoutes from (Seeking Alpha- comments)
“The most important thing here is that WHO chose ARCT for one of the 4 vaccine candidates and sponsor and fund phase 3 for arct021.
ARCT has very good mRNA platforms, and hence very valuable IPs. Arct021 was the original vaccine candidate to tackle covid19. With the emergence of variants, ARCT has quickly updated and came up with arct154 and arct165. If ARCT can get EUA in Vietnam for arct154, the potential would be immense. Arct021 is a one dose vaccine and that has a lot of advantages. Despite the fact that many may already have been vaccinated, but arct021 can still be effective as a one dose vaccine since from research reports, neutralising antibodies dropped to very low levels after 6 months with the other vaccines. So, arct021, arct154 and arct165 still have very good potentials in the vaccine market and can also be as booster shots.
In the future, if we have another outbreak of diseases, ARCT can be the go-to company to quickly develop a vaccine besides BionTech and Moderna. The mRNA platforms of ARCT, in my opinion, is better than its competitors. Some big pharmas are behind the curve in mRNA technology and they may look to acquire ARCT. The only weakness for ARCT was that it was a standalone biotech and there was no support or tie-up with another big pharma during the covid crisis as compared to BionTech with Pfizer, and Moderna getting lots of funding etc....” qoutes from (Seeking Alpha- comments)
6
2
我描述股票購買的超級外行方式-
-當我年輕時(沒有承諾,但有潛力)購買股票就像尋找女朋友/男朋友。我有時間,但有限的資本在我的手-舉起我的賭注,並承擔風險!乘浪,但從錯誤中學習。我贏了一些,也輸了一些!
-當我年齡(有承諾,但不少潛力 🤣)購買股票就像尋找潛在的合作夥伴-知道您想購買哪些股票(包括研究和圖表),以及即使市場下跌,您願意對公司的未來投資/信心多少。穩定性和安全性
關於股票賣出的部分-
-每個人似乎都有他們想要的東西或何時出售的目標價格。我還沒有掌握銷售部分,因為我的目標是保持與這些公司的長期合作關係。我太擁有或者 🤔 太舒服了,不承擔任何更多的風險??!!也許就像老夫婦!
教我什麼時候放手🤣🤣 我還在學習。... 😊
-當我年輕時(沒有承諾,但有潛力)購買股票就像尋找女朋友/男朋友。我有時間,但有限的資本在我的手-舉起我的賭注,並承擔風險!乘浪,但從錯誤中學習。我贏了一些,也輸了一些!
-當我年齡(有承諾,但不少潛力 🤣)購買股票就像尋找潛在的合作夥伴-知道您想購買哪些股票(包括研究和圖表),以及即使市場下跌,您願意對公司的未來投資/信心多少。穩定性和安全性
關於股票賣出的部分-
-每個人似乎都有他們想要的東西或何時出售的目標價格。我還沒有掌握銷售部分,因為我的目標是保持與這些公司的長期合作關係。我太擁有或者 🤔 太舒服了,不承擔任何更多的風險??!!也許就像老夫婦!
教我什麼時候放手🤣🤣 我還在學習。... 😊
已翻譯
1
2
AstroGal樓主 : 哦.. 哇!!我沒有在單獨的獎勵兌換中看到它們,但感謝您提供的信息,我將確保在下次使用我的積分之前檢查了所有內容!